CSF1R and glioblastoma: Supporting this concept, a CSF1R‐targeting antibody considerably enhances the efficacy of focal RT given in five daily fractions of 2 Gy each in preclinical GBM models, further extending the survival of GBM‐bearing mice (Akkari et al, 2020).